Active immunotherapy enhances the patient's antitumor immunity and serves as an effective adjunct to the surgical treatment of stomach cancer.
Timely surgical treatment of stomach cancer can lead to full recovery. However, at advanced stages, when radical surgery is impossible, the prognosis is unfavorable — despite chemotherapy.
Immunotherapy aimed at enhancing the patient's antitumor immunity is considered an effective addition to the surgical treatment of this disease.
Vaccine-induced immune processes destroy tumor cells and prevent disease relapse.
Includes 10 subcutaneous vaccinations and takes approximately 3 months. Treatment is performed on an outpatient basis.
Includes 10 subcutaneous vaccinations and takes approximately 3 months. Treatment is performed on an outpatient basis.
During the first 24 hours after vaccination, a temperature rise up to 38°C and flu-like symptoms may occur — a sign of immune activation.
During the first 24 hours after vaccination, a temperature rise up to 38°C and flu-like symptoms may occur — a sign of immune activation.
Vaccine-induced immune processes destroy tumor cells and impede relapse development.
Vaccine-induced immune processes destroy tumor cells and impede relapse development.
Further regimens are prescribed individually, depending on the stage of the disease and the patient's condition.
Further regimens are prescribed individually, depending on the stage of the disease and the patient's condition.
A clinical effect lasting at least 6 months is achieved in a significant portion of patients with stage IV stomach cancer.
Patient I., 54 years old
Poorly differentiated stomach adenocarcinoma, lung metastases
Baseline
Started treatment in moderate condition: weakness, fatigue, periodic vomiting, subfebrile temperature. During therapy — temperature rose to 38.5°C.
After 3 months
Lymph nodes in the porta hepatis, epigastrium, and retroperitoneum were not visualized. Blood tests showed ESR normalization and an increase in hemoglobin.
Observation period
All subsequent examinations revealed no pathological changes. 2.5 years after starting vaccine therapy, no signs of disease progression were observed.
No progression — observed for 2.5 years
Patient I., 44 years old
Signet ring cell carcinoma of the stomach post-gastrectomy
Baseline
Two months after gastrectomy and a course of polychemotherapy, progression was noted: enlarged lymph nodes in the porta hepatis and retroperitoneum. Vaccine therapy was initiated in an intensified regimen.
Dynamics
Tolerated the treatment well. Pain and redness at the injection site subsided after a few hours.
Observation period
Two years after the start of vaccine therapy, her condition is satisfactory, with no complaints.
Satisfactory condition — observed for 2 years
Immunotherapy is viewed as an effective complement to surgical treatment, enhancing antitumor immunity.
A clinical effect is achieved in a significant proportion of patients, even at stage IV of the disease.
Treatment is administered on an outpatient basis and is not accompanied by the severe toxicity associated with chemotherapy.
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.